SurModics — Investor Presentation (August 2019)
30 slides from SurModics's investor presentation, Aug 13, 2019
Slide 1: Surmodics Investor Presentation, August 2019
Gary MaharajPresident and CEOTim ArensVice President of Finance and CFOAugust 2019 1
Slide 2: Safe Harbor
Safe Harbor Some of the statements made during this presentation may be considered forward-looking statements. Statements that are not historical or current facts, including statements about beliefs and expectations regarding our performance in the near- and long-term, including our revenue and earn
Slide 3: Focused on product innovation
Focused on product innovation VISION3 of the Top 10 InnovationsFocused on PAD and designed to be: safe, clinically effective & improve healthcare economics IMPACT TO PATIENTSGrowing incidence of peripheral artery disease (PAD) IMPACT TO INVESTORSInvesting to build long-term sustainable growth and pr
Slide 4: Vision of the top 10 innovations in vascular medicine
) of the top10 © INJOVA r\ INNOVATIO in vascular medicine L by VISION of SURMODICS
Slide 5: Desired outcomes: patients with Peripheral Artery Disease
DESIRED OUTCOMESGoal of improving clinical outcomes while reducing healthcare costs PATIENTS202 million patients worldwide living with Peripheral Artery Disease (PAD) 5
Slide 6: Impact to patients
Impact to patients Product innovations aimed at making significant improvements in patient outcomes and quality of life (QOL) PATIENTS DESIRED OUTCOMES Superficial Femoral Artery (SFA)> 500K procedures annuallyPain on ambulation – reduced QOL Reduction in reintervention ratesImproved QOL by reductio
Slide 7: Whole product solutions strategy
7 Our whole product solutions strategy is focused on creating innovative, differentiated product platforms that solve clinically meaningful problems in treating peripheral vascular disease Desired OutcomesImprove Clinical OutcomesReduce Healthcare Costs Initial PlatformsDrug Coated BalloonsSurVeil™
Slide 8: SurVeil DCB 12-Month Data
SurVeil™ DCB 12-Month Data Uniform drug topcoatPaclitaxel + proprietary excipient2.0 µg/mm² drug load360°coating coverage 0.035” OTW PTA platform4–7 mm x 40–150 mm Shaft coatingSerene® hydrophilic coating Proprietary PhotoLink® basecoat “The ongoing positive results from this study demonstrate that
Slide 9: Current debate on paclitaxel-coated devices to treat PAD
CURRENT DEBATE ON PACLITAXEL-coated DEVICES TO TREAT PAD 9 RECAP OF RECENTS EVENTS JANUARY 17FDA CommunicationBenefits outweigh risks 2018 DECEMBER 8 Katsanos Meta-Analysispublished in JAHA SRDX DISCUSSIONS with FDA MARCH 2-3VIVA ForumIn-depth review JUNE 19-20FDA PanelMeeting 2019 DEC JAN FEB MAR A
Slide 10: FDA Panel Advisory Committee Meeting highlights
FDA PANEL Advisory Committee Meeting MEETING HIGHLIGHTS – JUNE 19-20, 2019Signal present from meta-analysis, no plausible cause identifiedTotality of data should include large well-constructed observational studies where no signal has been foundBenefits of paclitaxel-coated devices are significant,
Slide 11: December 8: Katsanos meta-analysis
December 8: Katsanos meta-analysis Meta-Analysis Limitations:No access to patient-level dataNo plausible mechanism of action notedQuestions regarding statistical model usedSelection bias due to lack of complete follow upLost to follow up and withdrawals are not accurately or completely accountedPTA
Slide 12: August update: FDA Communication to Health Care Providers
AUGUST 7 – UPDATE: FDA Communication to Health Care Providers Update to January 17 and March 15 FDA notificationsFDA is taking additional steps to address the safety signal, including working with manufacturers on updates to device labeling and clinical trial informed consent documentsFDA is also co
Slide 13: FDA Recommendations to US Health Care Providers
FDA Recommendations to US Health Care Providers (March 15 and August 7 Letters) 13 March 15, 2019 Letter August 7, 2019 Letter Continue diligent monitoring of patients Continue diligent monitoring of patients Evaluate and inform of potential risks Evaluate and inform of potential risks Consider ther
Slide 14: TRANSCEND: SurVeil DCB Pivotal Trial
TRANSCEND: SURVEIL™ DCB PIVOTAL TRIAL PRINCIPAL INVESTIGATORSWilliam (Bill) Gray, MD, FACC, FSCAIClinical Advisor — Main Line Health, Inc., Wynnewood, PAKenneth Rosenfield, MD Chair Advisory Board — Interventional Cardiology, Mass. General HospitalMarianne Brodmann MD, PhD Clinical Advisor — Interve
Slide 15: Strategic Agreement with Abbott
Strategic Agreement with Abbott Demonstrates value of whole-product solutions strategyLeverages Surmodics’ leadership in drug-delivery technologies, design, development capabilities, and manufacturing capacityCombines with Abbott’s deep experience in vascular care products and worldwide strength in
Slide 16: Terms of Agreement
Terms of Agreement CAUTION: SurVeil™ Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use. 16 Exclusive worldwide commercialization rights for SurVeil™ drug-coated balloon (DCB) for superficial femoral artery (SFA)$25 million upfront paym
Slide 17: DCB platform extension
DCB platform extension Surmodics .014” PTA platform2 – 4 mm diameter20 – 220 mm lengths Uniform sirolimus drug coatingSirolimus + Proprietary Excipient360° uniform coating coverage Avess™ AV Fistula DCB VISION Surmodics .035” PTA platform4 – 12 mm diameter40 – 80 mm lengths Uniform paclitaxel drug c
Slide 18: Progress on Whole-Product Solutions Strategy
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 JANUARY 510 (K) Clearance for Telemark™ Coronary / Peripheral Support Catheter We Are Making Progress On Our Whole-Product Solutions Strategy 18 Drug-Coated Balloons (DCB) 510 (K) / CE Mark FY2017 SEPTEMBER Global Clearance of .014” Low-Profile PTA Balloon Cathete
Slide 19: Pounce Thrombectomy Platform Technology
POUNCE™ Thrombectomy Platform Technology Game-changing technology designed for removal of organized thrombi and emboli, in an approximately $400M growing global marketSimple stand-alone intervention, eliminates need for capital equipment and may reduce the need for thrombolytics and complex procedur
Slide 20: Radial Access Platform Technology
Radial Access Platform Technology 20 Radial artery access offers many benefits relative to femoral artery access including reduced bleeding complications, early ambulation, reduced length of stay and costsWidely adopted in coronary procedures where devices existInitial radial-based products in devel
Slide 21: Product Milestones
Product Milestones CAUTION: SurVeil™, Avess™ and Sundance™ Drug-Coated Balloons are investigational devices. Limited by Federal (or United States) law to investigational use. IMPACT TO INVESTORS CY 2019 GOALS FY 2019 – FY 2021 GOALS Enroll the TRANSCEND trial as fast as reasonable: complete enrollme
Slide 22: Pipeline products and financial performance targets
PIPELINE PRODUCTSSurVeil™ DCBSundance™ Below-the-knee DCBAvess™ AV DCBMultiple 510(k)’s Financial Performance Targets>10% revenue growth (achieved fiscal 2018 – on track for fiscal 2019)>30% EBITDA margin by 2021 22 The agreement with Abbott has a meaningful positive impact on our commitment to deli
Slide 23: Management Team
MANAGEMENT TEAM Gary R. MaharajPresident and Chief Executive Officer (2010) Timothy J. ArensVice President of Finance and Chief Financial Officer (2007) Joseph J. Stich Vice President and General Manager of In Vitro Diagnostics (2010) Thomas GreaneyChief Operating Officer of Medical Devices (2015) G
Slide 24: Clinical & Scientific Advisors
Clinical & scientific ADVISORS Ken Rosenfield, MD Chair Advisory Board — Interventional CardiologyMassachusetts General Hospital Gary Ansel, MD, FACC Clinical Advisor — Interventional CardiologyOhio Health Research Marianne Brodmann MD, PhD Clinical Advisor— Interventional CardiologyDivision of Angi
Slide 25: Surmodics business segments
Surmodicsbusiness segments For the nine months ended June 30, 2019 BUSINESSSEGMENTREVENUE IVDBUSINESS23% MEDICAL DEVICES77% 25
Slide 26: Surmodics Core Offerings
Surmodics CORE Offerings vascular access sheath coronary guidewire peripheral clad guidewire coronary stent delivery catheter coronary balloon dilatation catheter peripheral balloon dilatation catheter diagnostic guide catheter vascular access and support catheter MEDICAL DEVICE COATINGS IN VITRO DI
Slide 27: Quarterly and Annual Revenue
‘QUARTERLY REVENUE (MILLIONS) ANNUALREVENUE (MILLIONS) si, $92.0 $23.0 5207 $94.0 $22.2 $813 42018 12019 Q22019 932019 2016 2017 2018 20198 of SURMODICS
Slide 28: Financials by Segment
FINANCIALS BY SEGMENT MISSION: To improve the treatment and detection of diseaseStrong balance sheet and attractive cash flows to fund growth strategy$45.0 million of cash/investments as of June 30, 2019Operating cash flow of $34.1 million and adjusted EBITDA of $7.3 million in fiscal 2018 MEDICAL D
Slide 29: 2019 Guidance and Long Term Objectives
2019 Guidance 2019 Financial Guidance Long Term Objectives Total Revenue: $92.0 million to $94.0 million (includes $7.5 million to $8.0 million of SurVeil™ DCB revenue)(1) GAAP Earnings per Share(2): $0.24 to $0.32Non-GAAP Earnings per Share(2): $0.41 to $0.49 Continue consistent double-digit top li
Slide 30: Investor Relations
INVESTOR RELATIONSFor additional inquiries, please contact:Tim Arens • 952-500-7056 30